Benznidazole: Hero or villain of cellular immune response in chronic Chagas disease patients?

[1]  M. C. Thomas,et al.  Immunological exhaustion and functional profile of CD8+ T lymphocytes as cellular biomarkers of therapeutic efficacy in chronic Chagas patients. , 2020, Acta tropica.

[2]  S. Laucella,et al.  Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease , 2015, Memorias do Instituto Oswaldo Cruz.

[3]  Michael P. Barrett,et al.  Management of trypanosomiasis and leishmaniasis , 2012, British medical bulletin.

[4]  M. Guariento,et al.  Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole , 2011, Tropical medicine & international health : TM & IH.

[5]  S. Yusuf,et al.  The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[6]  R. Favaloro,et al.  Accurate Real-Time PCR Strategy for Monitoring Bloodstream Parasitic Loads in Chagas Disease Patients , 2009, PLoS neglected tropical diseases.

[7]  S. Yusuf,et al.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). , 2008, American heart journal.

[8]  A. Teixeira-Carvalho,et al.  Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern. , 2008, Microbes and infection.

[9]  A. Teixeira-Carvalho,et al.  Benznidazole Treatment during Early‐indeterminate Chagas’ Disease Shifted the Cytokine Expression by Innate and Adaptive Immunity Cells toward a Type 1‐modulated Immune Profile , 2006, Scandinavian journal of immunology.

[10]  M. O. Rocha,et al.  Monocytes from Patients with Indeterminate and Cardiac Forms of Chagas' Disease Display Distinct Phenotypic and Functional Characteristics Associated with Morbidity , 2004, Infection and Immunity.

[11]  P. Groscurth,et al.  Morphological features of cell death. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[12]  T. Araújo-Jorge,et al.  Benznidazole Treatment following Acute Trypanosoma cruzi Infection Triggers CD8+ T-Cell Expansion and Promotes Resistance to Reinfection , 2002, Antimicrobial Agents and Chemotherapy.

[13]  R. Gazzinelli,et al.  Chemokines, inflammation and Trypanosoma cruzi infection. , 2002, Trends in parasitology.

[14]  T. Espevik,et al.  The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF1 , 2002, The Journal of Immunology.

[15]  J. R. Cançado.  Long term evaluation of etiological treatment of chagas disease with benznidazole. , 2002, Revista do Instituto de Medicina Tropical de Sao Paulo.

[16]  J. Coura,et al.  A critical review on Chagas disease chemotherapy. , 2002 .

[17]  A. Simoes-Barbosa,et al.  Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. , 2000, The American journal of tropical medicine and hygiene.

[18]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.

[19]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[20]  F. Kierszenbaum,et al.  Modulation of sensitivity of blood forms of Trypanosoma cruzi to antibody-mediated, complement-dependent lysis , 1990, Infection and immunity.